2020
Onconephrology: The intersections between the kidney and cancer
Rosner MH, Jhaveri KD, McMahon BA, Perazella MA. Onconephrology: The intersections between the kidney and cancer. CA A Cancer Journal For Clinicians 2020, 71: 47-77. PMID: 32853404, DOI: 10.3322/caac.21636.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsHumansInterdisciplinary CommunicationKidney DiseasesMedical OncologyNeoplasmsNephrologyStem Cell TransplantationConceptsChronic kidney diseaseDrug-induced nephrotoxicityKidney diseaseElectrolyte disordersAcute kidney injuryStem cell transplantationParaneoplastic glomerulonephritisKidney injuryCell transplantationTherapeutic regimensCollaborative careCancerDiseasePatientsOnconephrologyNew subspecialtySpecific training programsNephrotoxicityDisordersTraining programGlomerulonephritisRegimensNephrologistsTransplantationOncologistsHow to determine kidney function in cancer patients?
Sprangers B, Abudayyeh A, Latcha S, Perazella MA, Jhaveri KD. How to determine kidney function in cancer patients? European Journal Of Cancer 2020, 132: 141-149. PMID: 32361629, DOI: 10.1016/j.ejca.2020.03.026.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsGlomerular Filtration RateHumansKidney Function TestsNeoplasmsPrognosisRenal Insufficiency, ChronicConceptsGlomerular filtration rateKidney functionCancer patientsDifferent glomerular filtration ratesAppropriate dose adjustmentCKD-EPI formulaSerum creatinine concentrationNarrow therapeutic indexDose adjustmentFiltration rateClinical trialsCreatinine concentrationTherapeutic indexAnti-cancer drugsPatientsToxic drugsDrugsBody surfaceTrials
2019
Improving Cancer Care for Patients With Chronic Kidney Disease.
Sprangers B, Jhaveri KD, Perazella MA. Improving Cancer Care for Patients With Chronic Kidney Disease. Journal Of Clinical Oncology 2019, 38: 188-192. PMID: 31800342, DOI: 10.1200/jco.19.02138.Peer-Reviewed Original Research
2015
Thrombotic Microangiopathy, Cancer, and Cancer Drugs
Izzedine H, Perazella MA. Thrombotic Microangiopathy, Cancer, and Cancer Drugs. American Journal Of Kidney Diseases 2015, 66: 857-868. PMID: 25943718, DOI: 10.1053/j.ajkd.2015.02.340.Peer-Reviewed Original ResearchConceptsDrug-induced thrombotic microangiopathyThrombotic microangiopathyAnti-vascular endothelial growth factor agentsEndothelial growth factor agentsLong-term kidney injuryManagement of TMACell damageGrowth factor agentsAnti-VEGF agentsEndothelial cell damageType I agentsChemotherapy regimensDrug interruptionFactor agentsKidney injuryImmunologic basisClinical courseFunctional recoveryImmunosuppressive agentsKidney functionCertain malignanciesI agentsPhysician guidanceAnticancer therapySuccessful diagnosisNew drug toxicities in the onco-nephrology world
Perazella MA, Izzedine H. New drug toxicities in the onco-nephrology world. Kidney International 2015, 87: 909-917. PMID: 25671763, DOI: 10.1038/ki.2015.30.Peer-Reviewed Original ResearchConceptsKidney injuryAnticancer medicationsAdverse renal consequencesAcute kidney injuryChronic kidney diseaseLevel of proteinuriaMore effective therapiesRenal consequencesElectrolyte disturbancesKidney diseaseNephrotoxic effectsNephrotoxic potentialRisk factorsEffective therapyNephrotoxic manifestationsDrug toxicityNew agentsOld drugsNephrology communityResistant cancersClinical arenaAvailable evidenceMedicationsPatientsInjury